Last reviewed · How we verify
Voglibose + Metformin
Voglibose inhibits intestinal α-glucosidases to slow glucose absorption, while metformin reduces hepatic glucose production and improves insulin sensitivity.
Voglibose inhibits intestinal α-glucosidases to slow glucose absorption, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Voglibose + Metformin |
|---|---|
| Sponsor | University of Zambia |
| Drug class | α-glucosidase inhibitor + biguanide combination |
| Target | α-glucosidase enzymes; AMPK pathway / mitochondrial complex I |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Voglibose is an α-glucosidase inhibitor that delays carbohydrate digestion and glucose absorption in the small intestine, reducing postprandial blood glucose spikes. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they provide complementary mechanisms to improve glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (diarrhea, flatulence, abdominal discomfort)
- Lactic acidosis (metformin-related, rare)
- Hypoglycemia (when combined with other agents)
- Nausea
Key clinical trials
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
- Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes (PHASE4)
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Incretin-based Drugs and Pancreatic Cancer
- Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Glucose Reduction by Early Acarbose Treatment in Basal Insulin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Voglibose + Metformin CI brief — competitive landscape report
- Voglibose + Metformin updates RSS · CI watch RSS
- University of Zambia portfolio CI